Search
Close this search box.
Search
[custom_company_search_form]
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)
Lithium
42.50
(2.03%)
Gold
2,678.60
(0.03%)
Copper
4.34
0.01%
Oil
70.94
(0.07%)
Bitcoin
66,838.13
1.17%
FTSE 100
8,249.28
(0.52%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,740.42
(1.16%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.08%)
Hang Seng
20,318.79
(3.46%)

Amplia Therapeutics Ltd

ATX

ASX

Amplia Therapeutics Limited (ATX) is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and ovarian cancers. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Latest Posts

Line Chart with Gradient
Price
$0.15
0 (0%)
At Close 14/10 (AEST)
Related Companies
SYNTARA LIMITED
$SNT
BPH GLOBAL LTD
$BP8DD
MEDLAB CLINICAL LIMITED
$MDC
WELLFULLY LIMITED
$WFL
AFT PHARMACEUTICALS LIMITED
$AFP

Latest Posts

amplia-therapeutics-asx-atx-secures-fda-fast-track-designation-for-narmafotinib-in-advanced-pancreatic-cancer-atx
Health Care $ATX

Amplia Therapeutics (ASX: $ATX) secures fda fast track designation for narmafotinib in advanced pancreatic cancer

FDA fast track designation facilitates expedited review for promising FAK inhibitor in pancreatic cancer treatment

September 20, 2024
amplia-therapeutics-asx-atx-secures-key-chemical-form-patent-in-europe-and-japan-atx
Health Care $ATX

Amplia Therapeutics (ASX: $ATX) secures key chemical form patent in europe and japan

Patent protection for narmafotinib extended to at least 2040 in major markets

August 7, 2024
amplia-therapeutics-asx-atx-completes-recruitment-for-phase-2a-accent-trial-atx
Health Care $ATX

Amplia Therapeutics (ASX: $ATX) completes recruitment for phase 2a ACCENT trial

Phase 2a trial explores narmafotinib in combination with standard-of-care chemotherapy for advanced pancreatic cancer patients

July 4, 2024
amplia-therapeutics-asx-atx-requests-trading-halt-for-entitlement-offer-process-atx
Health Care $ATX

Amplia Therapeutics (ASX: $ATX) requests trading halt for entitlement offer process

Company to release announcement regarding capital raising to end trading halt

April 12, 2024
amplia-therapeutics-asxatx-receives-approval-for-phase-2-accent-pancreatic-cancer-trial-in-korea-atx
Health Care $ATX

Amplia Therapeutics (ASX:ATX) receives approval for phase 2 accent pancreatic cancer trial in korea

Korean regulator approves clinical trial for narmafotinib in combination with gemcitabine and Abraxane®

December 3, 2023
amplia-therapeutics-asx-atx-progresses-pancreatic-cancer-trial-atx
Health Care $ATX

Amplia Therapeutics (ASX: $ATX) progresses pancreatic cancer trial

Phase 2a trial achieves required response rate with narmafotinib combination therapy

September 23, 2024

ATX

$ATX

Amplia Therapeutics (ASX: $ATX) secures fda fast track designation for narmafotinib in advanced pancreatic cancer

FDA fast track designation facilitates expedited review for promising FAK inhibitor in pancreatic cancer treatment

ATX

$ATX

Amplia Therapeutics (ASX: $ATX) secures key chemical form patent in europe and japan

Patent protection for narmafotinib extended to at least 2040 in major markets

ATX

$ATX

Amplia Therapeutics (ASX: $ATX) completes recruitment for phase 2a ACCENT trial

Phase 2a trial explores narmafotinib in combination with standard-of-care chemotherapy for advanced pancreatic cancer patients

ATX

$ATX

Amplia Therapeutics (ASX: $ATX) requests trading halt for entitlement offer process

Company to release announcement regarding capital raising to end trading halt

ATX

$ATX

Amplia Therapeutics (ASX:ATX) receives approval for phase 2 accent pancreatic cancer trial in korea

Korean regulator approves clinical trial for narmafotinib in combination with gemcitabine and Abraxane®

Related Companies
ORTHOCELL LIMITED
$OCC
LITTLE GREEN PHARMA LTD
$LGP
BIOTRON LIMITED
$BIT
BCAL DIAGNOSTICS LIMITED
$BDX
AROA BIOSURGERY LIMITED
$ARX

ASX News, First
& Fast.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

By clicking Subscribe, you agree to our Terms & Conditions

© 2024 Stock Piper. All rights reserved

© 2024 Stock Piper.
All rights reserved

Blog

Healthcare
Materials
Real Estate
Consumer Staples
Consumer Discretionary Brief
Utilities

Company

About us
Terms of use
Privacy Policy

Support

Request Form
Contact Support
FAQ
Glossary

Socials

Facebook
Twitter
LinkedIn
© 2024 Stock Piper. All rights reserved
Social Media Auto Publish Powered By : XYZScripts.com
Stock Piper AI Index
Subscribe
Join FREE Newsletter

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions